Beximco Pharmaceuticals (LSE:BXP) LT-Debt-to-Total-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Beximco Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beximco Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.02.

Beximco Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2022 (0.05) to Mar. 2024 (0.02). It may suggest that Beximco Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Beximco Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Beximco Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals LT-Debt-to-Total-Asset Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.03

0.02

0.05

0.04

Beximco Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.04	0.04	0.03	0.02

Beximco Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Beximco Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	17.372	/	470.989
	=	0.04

Beximco Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	10.923	/	478.252
	=	0.02

Beximco Pharmaceuticals (LSE:BXP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beximco Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (LSE:BXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (LSE:BXP) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

R2WA:Germany BXPHARMA:Bangladesh

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.